DANBURY, Conn., Sept. 24 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that it will be presenting at the following upcoming conferences:
- Fifth Annual JMP Securities Healthcare Conference, September 28, 2010 at 12:00 pm Eastern time at the New York Palace in New York, NY. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Biodel website www.biodel.com. Replays of the presentation will be available for 90 days.
- Cantor Catalyst Conference, September 29, 2010 at 3:00 pm Eastern time at the Le Parker Meridien in New York, NY.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel’s product candidates are developed using VIAdel technology, which reformulates existing FDA-approved peptide drugs. Biodel’s new drug application for its most advanced product candidate, Linjeta, has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product candidates include VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company’s website at www.biodel.com.
BIOD-G
CONTACT: Seth Lewis, +1-646-378-2952
SOURCE Biodel Inc.
